SEARCH:   Advanced

Blood, 1 March 2004, Vol. 103, No. 5, pp. 1934-1936. Prepublished online as a Blood First Edition Paper on November 20, 2003; DOI 10.1182/blood-2003-06-1919. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-06-1919v1 103/5/1934    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Wood, J. C. Articles by Coates, T. D. Search for Related Content PubMed PubMed Citation Articles by Wood, J. C. Articles by Coates, T. D. Related Collections Brief Reports Clinical Trials and Observations Red Cells Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  RED CELLS Brief report Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease John C. Wood, J. Michael Tyszka, Susan Carson, Marvin D. Nelson, and Thomas D. Coates From the Divisions of Pediatric Cardiology and Hematology and the Department of Pediatric Radiology, Childrens Hospital Los Angeles, Los Angeles, CA; and Department of Biology, Biological Imaging Center, California Institute of Technology, Pasadena, CA. Cardiac T2* (magnetic resonance imaging relaxation parameter) is abnormally low in approximately 40% of adults with thalassemia major (TM), suggesting myocardial iron deposition, but it is unknown at what age this occurs. To address this question, we measured cardiac T2* and function in 19 young patients (aged 7-26 years) with TM as well as 17 patients receiving long-term transfusions for sickle cell anemia (SCA) matched for age, sex, and liver iron content. Cardiac T2* was normal in all of the SCA patients but was low (high iron) in 8 of 19 TM patients. Abnormal T2* was observed only in the TM patients receiving transfusions for 13 years or longer and was correlated with ferritin but not liver iron levels. Cardiac dysfunction was present in 3 of the 8 patients with low T2*. Cardiac T2* changes have a long latency relative to liver iron accumulation. Total transfusional burden is a significant independent risk factor for low cardiac T2* and may partially account for differences observed between patients with SCA and TM. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Myocardial iron measurements by MRI: getting to the heart of the matter Ellis Neufeld Blood 2004 103: 1571. [Full Text] [PDF] This article has been cited by other articles: J. C. Wood, R. Origa, A. Agus, G. Matta, T. D. Coates, and R. Galanello Onset of cardiac iron loading in pediatric patients with thalassemia major Haematologica, June 1, 2008; 93(6): 917 - 920. [Abstract] [Full Text] [PDF] E. Angelucci, G. Barosi, C. Camaschella, M. D. Cappellini, M. Cazzola, R. Galanello, M. Marchetti, A. Piga, and S. Tura Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders Haematologica, May 1, 2008; 93(5): 741 - 752. [Abstract] [Full Text] [PDF] W. Li, T. Coates, and J. C. Wood Atrial dysfunction as a marker of iron cardiotoxicity in thalassemia major Haematologica, February 1, 2008; 93(2): 311 - 312. [Abstract] [Full Text] [PDF] M.A. Tanner, R. Galanello, C. Dessi, G.C. Smith, M.A. Westwood, A. Agus, M. Roughton, R. Assomull, S.V. Nair, J.M. Walker, et al. A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance Circulation, April 10, 2007; 115(14): 1876 - 1884. [Abstract] [Full Text] [PDF] D. J. Pennell, V. Berdoukas, M. Karagiorga, V. Ladis, A. Piga, A. Aessopos, E. D. Gotsis, M. A. Tanner, G. C. Smith, M. A. Westwood, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis Blood, May 1, 2006; 107(9): 3738 - 3744. [Abstract] [Full Text] [PDF] E. J. Neufeld Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions Blood, May 1, 2006; 107(9): 3436 - 3441. [Abstract] [Full Text] [PDF] J. C. Wood, M. Otto-Duessel, M. Aguilar, H. Nick, M. D. Nelson, T. D. Coates, H. Pollack, and R. Moats Cardiac Iron Determines Cardiac T2*, T2, and T1 in the Gerbil Model of Iron Cardiomyopathy Circulation, July 26, 2005; 112(4): 535 - 543. [Abstract] [Full Text] [PDF] A. R. Cohen, R. Galanello, D. J. Pennell, M. J. Cunningham, and E. Vichinsky Thalassemia Hematology, January 1, 2004; 2004(1): 14 - 34. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020